Beijing CRO Co. Ltd.

1. To evaluate the efficacy and safety of OMS0728 combined with ATO in the treatment of relapsed acute promyelocytic leukemia (APL) using ATRA combined with ATO as a control 2. To evaluate the efficacy and safety of OMS0728 alone in the treatment of refractory acute promyelocytic leukemia (APL) 3. To conduct a pharmacokinetic study of OMS0728

Healthy Chinese adults were used as research subjects to explore the pharmacokinetics and safety of TY-0201R when administered as a single dose of 4 mg or 8 mg and when administered as multiple doses of 8 mg for 7 days.

Patients with essential hypertension (grade 1 or 2) were given TY-0201R 8 mg or bisoprolol fumarate oral preparation (hereinafter referred to as oral preparation) 5 mg once a day for 8 weeks. The efficacy of TY-0201R was verified to be non-inferior to the oral preparation through a double-blind double-dummy, parallel controlled trial, and the safety was evaluated at the same time.